Home

Todd C Brady

CIK 1579179 · President and CEO · last filed 2026-06-05

Todd C Brady is a President and CEO who has filed 64 SEC Form 4 insider transactions across 7 companies since 2013. The most recent filing shows the insider bought $418.4K of ALDX on Jun 5, 2026. Across all open-market trades the lifetime net is +$612.6K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$2.55M

Companies

7

Total Filings

64

Lifetime Open-Market Net

$612.6K

Filer Profile

Reported Address
C/O EVOKE PHARMA, INC.
505 LOMAS SANTA FE DRIVE
SOLANA BEACH, CA 92075
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ALDX President and CEO 1,721,298 $1.48 $2.55M $589.8K 25 2026-06-05
Evoke Pharma Inc (EVOK) Delisted Director 0 $11.00 $0 $0 9 2025-12-17
F-star Therapeutics, Inc. (FSTX) Delisted Director 0 $7.12 $0 $0 3 2023-03-09
F-star Therapeutics, Inc. (SBPH) Delisted Director 15,004 — — $0 17 2020-11-23
Evoke Pharma Inc (OMED) Delisted Director 4,000 — — $22.8K 6 2018-04-27
Outlook Therapeutics, Inc. (ONSIZ) Delisted Director 153,288 — — $0 2 2017-10-30
Outlook Therapeutics, Inc. (ONSI.U) Delisted Director 124,303 — — $0 1 2016-05-18

Recent Filings

64 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-05 ALDX Buy (P) +250,000 $418.4K EDGAR
2025-12-17 Evoke Pharma Inc (EVOK) Delisted Mixed −27 $0 EDGAR
2025-05-22 Evoke Pharma Inc (EVOK) Delisted Grant (A) — $0 EDGAR
2025-03-06 ALDX Grant (A) — $0 EDGAR
2025-01-29 Evoke Pharma Inc (EVOK) Delisted Grant (A) — $0 EDGAR
2024-05-24 Evoke Pharma Inc (EVOK) Delisted Grant (A) — $0 EDGAR
2024-03-12 ALDX Mixed −183,238 -$580.8K EDGAR
2024-03-11 ALDX Notice (144) −183,238 -$595.5K EDGAR
2023-09-11 ALDX Mixed +199,251 -$382.2K EDGAR
2023-05-11 Evoke Pharma Inc (EVOK) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 64
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.